EORTC characterizes responders & survivors on pazopanib for advanced soft tissue sarcoma
(European Organisation for Research and Treatment of Cancer) An EORTC analysis appearing in Annals of Oncology confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma. Additionally, hemoglobin at baseline was found to be a new prognostic factor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 10, 2014 Category: Cancer & Oncology Source Type: news
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
New position to support global Phase 3 clinical trial with aldoxorubicin in soft tissue sarcomas
LOS ANGELES--(Healthcare Sales & Marketing Network)--CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncolog... Biopharmaceuticals, Oncology, PersonnelCytRx, Aldoxorubicin, Soft Tissue Sarcoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 16, 2014 Category: Pharmaceuticals Source Type: news
Joint EORTC-ESTRO session to focus on current developments in soft tissue sarcoma treatment
(European Organisation for Research and Treatment of Cancer) The EORTC will host a joint session with ESTRO at ESTRO 33 focusing on current developments in soft tissue sarcoma treatment. It will take place from 14:30- 16:00 on Monday, 07 April 2014 in Vienna, Austria and will be co-chaired by Professors Jean-Yves Blay of the Centre Leon Berard in Lyon, France and past EORTC President and Philippe Maingon of the Centre Georges-François-Leclerc in Dijon, France, and Chair of the EORTC Radiation Oncology Group. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 29, 2013 Category: Global & Universal Source Type: news
Loss of microRNA decoy might contribute to development of soft-tissue sarcoma
Researchers have discovered a novel mechanism responsible for the loss of a critical tumor-suppressor gene in rhabdomyosarcoma and other soft-tissue sarcomas, rare cancers that strike mainly children and often respond poorly to treatment. Their cause is largely unknown. Knowledge of the mechanism could guide the development of more effective therapies for these malignancies, say researchers who led the study at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 9, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Loss of MicroRNA decoy might contribute to development of soft-tissue sarcoma
(Ohio State University Wexner Medical Center) Researchers have discovered a novel mechanism responsible for the loss of a critical tumor-suppressor gene in rhabdomyosarcoma and other soft-tissue sarcomas, rare cancers that strike mainly children and often respond poorly to treatment. Their cause is largely unknown. Knowledge of the mechanism could guide the development of more effective therapies for these malignancies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 7, 2013 Category: Global & Universal Source Type: news
Oncos Therapeutics granted orphan drug designation for CGTG-102 in soft tissue sarcoma (STS) by FDA and EMA
Oncos Therapeutics Ltd, a private, clinical-stage biotechnology company focused on the development and commercialization of targeted oncolytic immunotherapies for solid tumors, announced today that the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted orphan drug designation for CGTG-102, a granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus (Ad5/3-D24-GMCSF) for the treatment of soft tissue sarcoma. "We are pleased to receive orphan drug designations for CGTG-102 from the two leading regulatory agencies in the world... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 2, 2013 Category: Consumer Health News Tags: Regulatory Affairs / Drug Approvals Source Type: news
Microwave Ablation Shows Promise For Relief Of Painful Bone And Soft-Tissue Tumors
First-of-its-kind research showed microwave ablation (MWA) therapy cut pain in half for patients with painful bone and soft-tissue tumors and took less time to complete than radiofrequency ablation. Pain relief lasted over 4 months on average and up to 15 months in some patients, according to results reported at the 29th Annual Meeting of the American Academy of Pain Medicine. Approximately 10,600 new cases of soft-tissue sarcoma and 2,570 new cases of bone sarcoma were diagnosed in the United States in 2009, according to statistics published through the American Cancer Society... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 15, 2013 Category: Consumer Health News Tags: Pain / Anesthetics Source Type: news
NCCN Announces Important Updates to Soft Tissue Sarcoma Guidelines
JENKINTOWN, Pa., May 10, 2006 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Soft Tissue Sarcoma Guidelines. The NCCN Clinical Practice Guidelines in Oncology™ are widely recognized and applied as the standard for clinical policy in oncology in both the community practice setting and in academic cancer centers. These guidelines are used extensively by managed care companies and by Medicare as the basis for coverage policies. These guidelines are updated continua... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - May 10, 2006 Category: Cancer & Oncology Source Type: news
